AstraZeneca to acquire TeneoTwo and its blood-cancer therapeutic
AstraZeneca announces plans to acquire TeneoTwo and its CD19/CD3 T-cell…
AstraZeneca announces plans to acquire TeneoTwo and its CD19/CD3 T-cell engager, TNB-486, in a deal worth up to $1.2bn.